EQS-Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray
Switzerland General Giancarlo Icardi Michael Miller Jack Weinstein Advita Lifescience Gmb Relief Therapeutics Holding Sa Key
Source: finanznachrichten.de